Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144908511> ?p ?o ?g. }
- W2144908511 endingPage "70" @default.
- W2144908511 startingPage "161" @default.
- W2144908511 abstract "To estimate the cost-effectiveness of belimumab in patients with systemic lupus erythematosus (SLE) presenting positive biomarkers and active disease despite standard treatment (ST), from the Spanish social perspective.A microsimulation model was used to estimate the cost-effectiveness of belimumab plus ST versus ST alone. A treatment duration of two years with a life-time horizon were considered. Efficacy data were obtained from belimumab clinical trials and the evolution of the disease was simulated from John Hopkins ´ patient cohort data in the United States. Utility data were obtained from literature review. Direct and indirect costs were calculated based on Spanish published data (€, 2014), applying a discount rate (DR) of 3% to both costs and effects. Results were expressed as incremental cost-effectiveness ratio (ICER) in terms of gained life years (LY) and quality of life adjusted life years (QALYs). Probabilistic (PSA) and deterministic sensitivity analyses (DR of 0% and 5%, 5-years treatment duration and excluding indirect costs) were performed to determine the robustness of the model.The incremental cost-effectiveness ratio (ICER) was 16,647€ per life year gained, with an incremental cost-utility ratio (ICUR) of 23,158€ per additional QALY gained. In 68% of the scenarios simulated in the PSA, belimumab was found to be a cost-effective alternative, considering a threshold of 30,000€/ QALY.Belimumab can be regarded as a cost-effective alternative from the Spanish social perspective.Objetivo: Estimar el coste-efectividad (CE) de belimumab en aquellos pacientes con biomarcadores positivos y enfermedad activa a pesar del tratamiento estandar (TE) desde la perspectiva social espanola. Métodos: A partir de un modelo de microsimulacion, que permite simular la evolucion natural de la enfermedad, se estimo el CE de belimumab + TE vs. TE. Se considero una duracion del tratamiento de dos anos y un horizonte temporal de toda la vida. La extrapolacion de eficacia a largo plazo se baso en los ensayos clinicos de belimumab y en la cohorte de pacientes John Hopkins de Estados Unidos; los datos de utilidades se obtuvieron de la literatura. Se calcularon costes directos e indirectos en base a datos espanoles publicados (€, 2014), aplicando una tasa de descuento (TD) del 3% tanto a costes como a efectos. Los resultados se expresaron como ratio coste- efectividad incremental (ICER) en terminos de anos de vida ganados (AVG) y anos de vida ajustados por calidad (AVAC). Se realizaron analisis de sensibilidad deterministicos (TD al 0% y 5%, duracion de tratamiento 5 anos y exclusion de costes indirectos) asi como probabilisticos (PSA). Resultados: El ICER de belimumab + TE vs. TE fue de 16.647€/ AVG y 23.158€/AVAC respectivamente. La variacion de la TD supuso la mayor variacion de los resultados respecto al escenario base. En el 68% de los escenarios simulados en el PSA, belimumab fue una alternativa coste-efectiva considerando como umbral 30.000€/AVAC. Conclusiones: Belimumab puede considerarse una alternativa coste-efectiva desde la perspectiva social espanola." @default.
- W2144908511 created "2016-06-24" @default.
- W2144908511 creator A5029294647 @default.
- W2144908511 creator A5048351661 @default.
- W2144908511 creator A5074514536 @default.
- W2144908511 creator A5088126751 @default.
- W2144908511 date "2015-05-01" @default.
- W2144908511 modified "2023-09-26" @default.
- W2144908511 title "[Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain]." @default.
- W2144908511 cites W1918221619 @default.
- W2144908511 cites W1988327351 @default.
- W2144908511 cites W1992001277 @default.
- W2144908511 cites W1994222210 @default.
- W2144908511 cites W2004227465 @default.
- W2144908511 cites W2017712577 @default.
- W2144908511 cites W2025029039 @default.
- W2144908511 cites W2034311567 @default.
- W2144908511 cites W2072817116 @default.
- W2144908511 cites W2076300443 @default.
- W2144908511 cites W2079469575 @default.
- W2144908511 cites W2082483135 @default.
- W2144908511 cites W2082584638 @default.
- W2144908511 cites W2083673932 @default.
- W2144908511 cites W2088550293 @default.
- W2144908511 cites W2109268320 @default.
- W2144908511 cites W2114332193 @default.
- W2144908511 cites W2114502919 @default.
- W2144908511 cites W2119296184 @default.
- W2144908511 cites W2130781410 @default.
- W2144908511 cites W2131457901 @default.
- W2144908511 cites W2133963500 @default.
- W2144908511 cites W2136021003 @default.
- W2144908511 cites W2136149088 @default.
- W2144908511 cites W2137107745 @default.
- W2144908511 cites W2140741940 @default.
- W2144908511 cites W2162053930 @default.
- W2144908511 cites W2170524712 @default.
- W2144908511 cites W2172108014 @default.
- W2144908511 cites W2235150943 @default.
- W2144908511 cites W2255119417 @default.
- W2144908511 doi "https://doi.org/10.7399/fh.2015.39.3.8814" @default.
- W2144908511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26005892" @default.
- W2144908511 hasPublicationYear "2015" @default.
- W2144908511 type Work @default.
- W2144908511 sameAs 2144908511 @default.
- W2144908511 citedByCount "5" @default.
- W2144908511 countsByYear W21449085112015 @default.
- W2144908511 countsByYear W21449085112017 @default.
- W2144908511 countsByYear W21449085112019 @default.
- W2144908511 countsByYear W21449085112021 @default.
- W2144908511 countsByYear W21449085112023 @default.
- W2144908511 crossrefType "journal-article" @default.
- W2144908511 hasAuthorship W2144908511A5029294647 @default.
- W2144908511 hasAuthorship W2144908511A5048351661 @default.
- W2144908511 hasAuthorship W2144908511A5074514536 @default.
- W2144908511 hasAuthorship W2144908511A5088126751 @default.
- W2144908511 hasConcept C112930515 @default.
- W2144908511 hasConcept C121955636 @default.
- W2144908511 hasConcept C126322002 @default.
- W2144908511 hasConcept C127454912 @default.
- W2144908511 hasConcept C144133560 @default.
- W2144908511 hasConcept C159654299 @default.
- W2144908511 hasConcept C170286685 @default.
- W2144908511 hasConcept C18903297 @default.
- W2144908511 hasConcept C203014093 @default.
- W2144908511 hasConcept C2778453870 @default.
- W2144908511 hasConcept C2781205201 @default.
- W2144908511 hasConcept C3019080777 @default.
- W2144908511 hasConcept C64332521 @default.
- W2144908511 hasConcept C6964187 @default.
- W2144908511 hasConcept C71924100 @default.
- W2144908511 hasConcept C72563966 @default.
- W2144908511 hasConcept C86803240 @default.
- W2144908511 hasConceptScore W2144908511C112930515 @default.
- W2144908511 hasConceptScore W2144908511C121955636 @default.
- W2144908511 hasConceptScore W2144908511C126322002 @default.
- W2144908511 hasConceptScore W2144908511C127454912 @default.
- W2144908511 hasConceptScore W2144908511C144133560 @default.
- W2144908511 hasConceptScore W2144908511C159654299 @default.
- W2144908511 hasConceptScore W2144908511C170286685 @default.
- W2144908511 hasConceptScore W2144908511C18903297 @default.
- W2144908511 hasConceptScore W2144908511C203014093 @default.
- W2144908511 hasConceptScore W2144908511C2778453870 @default.
- W2144908511 hasConceptScore W2144908511C2781205201 @default.
- W2144908511 hasConceptScore W2144908511C3019080777 @default.
- W2144908511 hasConceptScore W2144908511C64332521 @default.
- W2144908511 hasConceptScore W2144908511C6964187 @default.
- W2144908511 hasConceptScore W2144908511C71924100 @default.
- W2144908511 hasConceptScore W2144908511C72563966 @default.
- W2144908511 hasConceptScore W2144908511C86803240 @default.
- W2144908511 hasIssue "3" @default.
- W2144908511 hasLocation W21449085111 @default.
- W2144908511 hasOpenAccess W2144908511 @default.
- W2144908511 hasPrimaryLocation W21449085111 @default.
- W2144908511 hasRelatedWork W1911068332 @default.
- W2144908511 hasRelatedWork W1981122966 @default.
- W2144908511 hasRelatedWork W2009145803 @default.
- W2144908511 hasRelatedWork W2017657202 @default.